Pfizer ROA 1986-2025 | PFE
Current and historical return on assets (ROA) values for Pfizer (PFE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Pfizer ROA - Return on Assets Historical Data |
Date |
TTM Net Income |
Total Assets |
Return on Assets |
2025-06-30 |
$10.75B |
$206.10B |
5.08% |
2025-03-31 |
$7.88B |
$208.03B |
3.68% |
2024-12-31 |
$8.03B |
$213.40B |
3.69% |
2024-09-30 |
$4.25B |
$219.48B |
1.93% |
2024-06-30 |
$-2.60B |
$216.19B |
-1.18% |
2024-03-31 |
$-0.31B |
$221.10B |
-0.14% |
2023-12-31 |
$2.12B |
$226.50B |
0.99% |
2023-09-30 |
$10.48B |
$215.02B |
5.06% |
2023-06-30 |
$21.47B |
$220.17B |
10.63% |
2023-03-31 |
$29.05B |
$195.62B |
14.83% |
2022-12-31 |
$31.37B |
$197.21B |
16.26% |
2022-09-30 |
$29.77B |
$195.35B |
15.75% |
2022-06-30 |
$29.31B |
$195.29B |
15.85% |
2022-03-31 |
$24.97B |
$183.84B |
13.98% |
2021-12-31 |
$21.98B |
$181.48B |
12.75% |
2021-09-30 |
$19.43B |
$179.19B |
11.74% |
2021-06-30 |
$12.76B |
$169.92B |
7.71% |
2021-03-31 |
$10.68B |
$158.82B |
6.38% |
2020-12-31 |
$9.16B |
$154.23B |
5.41% |
2020-09-30 |
$7.73B |
$178.98B |
4.48% |
2020-06-30 |
$13.94B |
$177.93B |
8.17% |
2020-03-31 |
$15.50B |
$166.34B |
9.38% |
2019-12-31 |
$16.03B |
$167.59B |
9.87% |
2019-09-30 |
$16.22B |
$170.45B |
10.11% |
2019-06-30 |
$12.65B |
$156.20B |
7.92% |
2019-03-31 |
$11.48B |
$155.42B |
7.09% |
2018-12-31 |
$11.15B |
$159.42B |
6.79% |
2018-09-30 |
$23.82B |
$167.84B |
14.24% |
2018-06-30 |
$22.55B |
$164.98B |
13.39% |
2018-03-31 |
$21.75B |
$164.61B |
12.85% |
2017-12-31 |
$21.31B |
$171.80B |
12.51% |
2017-09-30 |
$9.81B |
$172.15B |
5.76% |
2017-06-30 |
$8.32B |
$168.56B |
4.84% |
2017-03-31 |
$7.30B |
$168.78B |
4.23% |
2016-12-31 |
$7.22B |
$171.62B |
4.22% |
2016-09-30 |
$6.27B |
$178.43B |
3.69% |
2016-06-30 |
$7.04B |
$170.66B |
4.19% |
2016-03-31 |
$7.62B |
$162.93B |
4.61% |
2015-12-31 |
$6.96B |
$167.38B |
4.22% |
2015-09-30 |
$8.36B |
$170.87B |
5.07% |
2015-06-30 |
$8.90B |
$160.88B |
5.39% |
2015-03-31 |
$9.18B |
$160.64B |
5.46% |
2014-12-31 |
$9.14B |
$167.57B |
5.35% |
2014-09-30 |
$10.48B |
$171.36B |
6.09% |
2014-06-30 |
$10.40B |
$172.61B |
6.01% |
2014-03-31 |
$21.58B |
$171.81B |
12.35% |
2013-12-31 |
$22.00B |
$172.10B |
12.32% |
2013-09-30 |
$25.75B |
$175.52B |
14.15% |
2013-06-30 |
$26.37B |
$179.34B |
14.35% |
2013-03-31 |
$15.53B |
$187.40B |
8.41% |
2012-12-31 |
$14.57B |
$185.80B |
7.91% |
2012-09-30 |
$9.69B |
$182.60B |
5.25% |
2012-06-30 |
$10.22B |
$182.84B |
5.43% |
2012-03-31 |
$9.58B |
$185.68B |
5.00% |
2011-12-31 |
$10.01B |
$188.00B |
5.17% |
2011-09-30 |
$11.46B |
$196.13B |
5.86% |
2011-06-30 |
$8.59B |
$195.90B |
4.42% |
2011-03-31 |
$8.45B |
$194.96B |
4.38% |
2010-12-31 |
$8.26B |
$195.01B |
4.27% |
2010-09-30 |
$6.13B |
$191.42B |
3.10% |
2010-06-30 |
$8.15B |
$191.07B |
4.40% |
2010-03-31 |
$7.93B |
$195.11B |
4.61% |
2009-12-31 |
$8.64B |
$212.95B |
5.60% |
2009-09-30 |
$8.13B |
$141.29B |
6.32% |
2009-06-30 |
$7.53B |
$139.34B |
6.17% |
2009-03-31 |
$8.05B |
$122.93B |
6.91% |
2008-12-31 |
$8.10B |
$111.15B |
7.02% |
2008-09-30 |
$10.56B |
$115.25B |
9.07% |
2008-06-30 |
$9.05B |
$116.52B |
7.88% |
2008-03-31 |
$7.54B |
$118.55B |
6.65% |
2007-12-31 |
$8.14B |
$115.27B |
7.32% |
2007-09-30 |
$14.87B |
$109.03B |
13.35% |
2007-06-30 |
$17.47B |
$110.40B |
15.70% |
2007-03-31 |
$18.62B |
$110.48B |
16.69% |
2006-12-31 |
$19.34B |
$115.55B |
17.24% |
2006-09-30 |
$12.62B |
$108.59B |
11.22% |
2006-06-30 |
$10.85B |
$111.55B |
9.60% |
2006-03-31 |
$11.90B |
$112.96B |
10.51% |
2005-12-31 |
$8.09B |
$116.97B |
6.99% |
2005-09-30 |
$8.18B |
$110.34B |
6.98% |
2005-06-30 |
$9.93B |
$112.33B |
8.27% |
2005-03-31 |
$9.33B |
$122.94B |
7.65% |
2004-12-31 |
$11.36B |
$123.08B |
9.32% |
2004-09-30 |
$9.14B |
$122.23B |
7.59% |
2004-06-30 |
$8.03B |
$119.96B |
6.70% |
2004-03-31 |
$1.58B |
$122.29B |
1.30% |
2003-12-31 |
$3.91B |
$116.78B |
3.78% |
2003-09-30 |
$6.17B |
$120.06B |
7.18% |
2003-06-30 |
$6.28B |
$124.26B |
9.36% |
2003-03-31 |
$11.83B |
$52.93B |
25.34% |
2002-12-31 |
$9.13B |
$46.36B |
20.85% |
2002-09-30 |
$8.23B |
$44.88B |
19.60% |
2002-06-30 |
$7.95B |
$42.57B |
19.65% |
2002-03-31 |
$7.82B |
$41.32B |
20.03% |
2001-12-31 |
$7.79B |
$39.15B |
20.76% |
2001-09-30 |
$7.25B |
$38.81B |
20.09% |
2001-06-30 |
$6.54B |
$36.94B |
18.81% |
2001-03-31 |
$5.86B |
$35.15B |
17.47% |
2000-12-31 |
$3.73B |
$33.51B |
12.50% |
2000-09-30 |
$3.26B |
$33.49B |
12.27% |
2000-06-30 |
$3.30B |
$32.04B |
14.17% |
2000-03-31 |
$2.86B |
$20.23B |
14.16% |
1999-12-31 |
$3.88B |
$20.57B |
19.50% |
1999-09-30 |
$3.63B |
$20.24B |
18.82% |
1999-06-30 |
$3.63B |
$19.64B |
19.33% |
1999-03-31 |
$3.55B |
$19.03B |
19.72% |
1998-12-31 |
$3.43B |
$18.30B |
19.89% |
1998-09-30 |
$3.28B |
$18.18B |
19.86% |
1998-06-30 |
$2.47B |
$16.51B |
15.67% |
1998-03-31 |
$2.30B |
$15.96B |
14.77% |
1997-12-31 |
$2.21B |
$15.34B |
14.40% |
1997-09-30 |
$2.16B |
$15.35B |
14.20% |
1997-06-30 |
$2.08B |
$15.73B |
13.83% |
1997-03-31 |
$2.01B |
$15.05B |
13.90% |
1996-12-31 |
$1.93B |
$14.67B |
13.76% |
1996-09-30 |
$1.84B |
$14.62B |
13.57% |
1996-06-30 |
$1.75B |
$13.62B |
13.35% |
1996-03-31 |
$1.67B |
$13.17B |
12.92% |
1995-12-31 |
$1.57B |
$12.73B |
12.33% |
1995-09-30 |
$1.50B |
$12.82B |
12.11% |
1995-06-30 |
$1.41B |
$12.95B |
11.98% |
1995-03-31 |
$1.35B |
$12.52B |
12.22% |
1994-12-31 |
$1.30B |
$11.10B |
12.60% |
1994-09-30 |
$1.25B |
$10.40B |
12.71% |
1994-06-30 |
$0.70B |
$10.10B |
7.22% |
1994-03-31 |
$0.70B |
$9.64B |
7.20% |
1993-12-31 |
$0.66B |
$9.33B |
6.76% |
1993-09-30 |
$0.65B |
$9.88B |
6.61% |
1993-06-30 |
$1.16B |
$10.02B |
11.76% |
1993-03-31 |
$1.13B |
$9.72B |
11.55% |
1992-12-31 |
$1.08B |
$9.59B |
11.11% |
1992-09-30 |
$0.80B |
$10.13B |
8.23% |
1992-06-30 |
$0.78B |
$9.56B |
8.23% |
1992-03-31 |
$0.73B |
$9.47B |
7.95% |
1991-12-31 |
$0.72B |
$9.64B |
7.96% |
1991-09-30 |
$0.88B |
$9.01B |
9.82% |
1991-06-30 |
$0.84B |
$8.83B |
9.58% |
1991-03-31 |
$0.82B |
$8.81B |
9.46% |
1990-12-31 |
$0.80B |
$9.05B |
9.53% |
1990-09-30 |
$0.73B |
$8.53B |
8.91% |
1990-06-30 |
$0.71B |
$8.10B |
8.82% |
1990-03-31 |
$0.69B |
$7.96B |
8.76% |
1989-12-31 |
$0.68B |
$8.33B |
8.71% |
1989-09-30 |
$0.74B |
$7.73B |
9.63% |
1989-06-30 |
$0.74B |
$7.65B |
9.75% |
1989-03-31 |
$0.81B |
$7.60B |
10.94% |
1988-12-31 |
$0.79B |
$7.64B |
10.89% |
1988-09-30 |
$0.79B |
$7.30B |
11.09% |
1988-06-30 |
$0.76B |
$7.20B |
11.23% |
1988-03-31 |
$0.72B |
$6.96B |
11.31% |
1987-12-31 |
$0.69B |
$6.92B |
11.59% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|